Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study
Por:
Marignier, R, Villacieros-alvarez, J, Espejo, C, Arrambide, G, Fissolo, N, Gutiérrez, L, Dinoto, A, Mulero, P, Rubio-Flores, L, Nieto, P, Alcalá, C, Meca-Lallana, JE, Martínez-Garcia, P, Millán, J, Bernard-Valnet, R, González, I, García, AO, Tellez, R, Navarro, L, Presas-Rodríguez, S, Romero-Pinel, L, Martínez-Yélamos, S, Cuello, JP, Torres, AMA, Piñar, R, Bravo, GA, Benyahya, L, Trouillet-Assant, S, Dyon-Tafani, V, Tilikete, CF, Ruet, A, Bourre, B, Deschamps, R, Papeix, C, Maillart, E, Kerschen, P, Ayrignac, X, Rovira, A, Auger, C, Audoin, B, Montalban, X, Tintore, M, Mariotto, S and Cobo-Calvo, A
Publicada:
1 sep 2025
Ahead of Print:
1 feb 2025
Resumen:
Background Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) have emerged as important biomarkers in multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD). However, their interest in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remains unclear. Our aim was to characterise sNfL and sGFAP profile and analyse their usefulness in predicting relapses and disability in MOGAD. Methods Retrospective study of adult MOGAD patients with serum samples collected at baseline (<= 3 months from disease onset) and follow-up (>6 months from baseline sample). sNfL and sGFAP were analysed using Simoa HD-1, and values were compared across time-points. The association between biomarkers and clinical variables and their predictive value for disability and relapses were analysed. Results Eighty-nine MOGAD patients were included. Baseline sNfL and sGFAP values were high at baseline and decreased over time (p<0.001, p=0.027, respectively). sNfL and sGFAP values were associated with Expanded Disability Status Scale (EDSS) at attacks (beta 0.15 (0.06; 0.25), p=0.002; beta 0.14 (0.07; 0.21), p<0.001, respectively) and were lower in optic neuritis presentations (beta -0.69 (-1.18; -0.19), p=0.007; beta -0.42 (-0.76; -0.08), p=0.016). Biomarker deltas[Delta] (baseline values - second samples values) were associated with Delta EDSS (initial EDSS - final EDSS) (Delta sNfL beta 0.52 (0.01; 1.04), p=0.046; Delta sGFAP beta 1.07 (0.38; 1.75), p=0.003). Finally, sNfL values independently predicted the risk of relapses (HR 2.06 (1.41; 3.01), p<0.001). Conclusions Our results on sNfL and sGFAP suggest initial neuro-axonal and astrocytic damage in MOGAD and the utility of these biomarkers at onset and follow-up in predicting clinical recovery and relapses.
Filiaciones:
Marignier, R:
Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Serv Neurol, Sclerose Plaques Pathol Myeline & Neuroinflammat, Lyon, France
Villacieros-alvarez, J:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
Espejo, C:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
Arrambide, G:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
Fissolo, N:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
Gutiérrez, L:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
Dinoto, A:
Hosp Clin Univ Valladolid, Serv Neurol, Valladolid, Spain
Mulero, P:
Aravaca & Arturo Soria Univ Hosp, Vithas La Milagrosa, Synaptia Madrid Neurosci, Madrid, Spain
Rubio-Flores, L:
Hosp Univ Rey Juan Carlos, Serv Neurocirugia, Madrid, Spain
Hosp Univ & Politecn La Fe, Unidad Neuroinmunol, Valencia, Spain
Nieto, P:
Hosp Univ & Politecn La Fe, Unidad Neuroinmunol, Valencia, Spain
Alcalá, C:
Virgen La Arrixaca Clin Univ Hosp, Neurol Dept, Multiple Sclerosis CSUR, Clin Neuroimmunol Unit,IMIB Arrixaca, Murcia, Spain
UCAM San Antonio Catholic Univ, NICEM Cathedra, Murcia, Spain
Meca-Lallana, JE:
Univ Lausanne, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland
Martínez-Garcia, P:
Univ Lausanne, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland
Millán, J:
Univ Lausanne, Lausanne Univ Hosp, Ctr Hosp Univ Vaudois, Lausanne, Switzerland
Bernard-Valnet, R:
Hosp Gen Univ Elche, Dept Neurol, Alicante, Spain
González, I:
Germans Trias & Pujol Hosp, Radiol Dept, Barcelona, Spain
García, AO:
Hosp Univ Bellvitge, Dept Clin Sci,Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL,Neurol & Neur, Sch Med,Multiple Sclerosis Unit,Dept Neurol,Neuros, LHospitalet De Llobregat, Barcelona, Spain
Tellez, R:
Hosp Univ Bellvitge, Dept Clin Sci,Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL,Neurol & Neur, Sch Med,Multiple Sclerosis Unit,Dept Neurol,Neuros, LHospitalet De Llobregat, Barcelona, Spain
Navarro, L:
Hosp Reg Univ Malaga, Malaga, Spain
:
Hosp Univ Clin San Cecilio, Serv Neurol, Granada, Spain
Romero-Pinel, L:
Hosp Univ Girona Dr Josep Trueta, Hosp Santa Caterina, Unitat Neuroimmunol & Esclerosi Multiple Terr Giro, Girona 17190, Spain
Martínez-Yélamos, S:
Hosp Univ Girona Dr Josep Trueta, Hosp Santa Caterina, Unitat Neuroimmunol & Esclerosi Multiple Terr Giro, Girona 17190, Spain
Cuello, JP:
Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Neuropsychol Lab, Bron, France
Torres, AMA:
Ctr Hosp Univ Bordeaux, Bordeaux, France
Piñar, R:
CHU Hop Rouen, Rouen, France
Bravo, GA:
Fdn Adolphe Rothschild Hosp, Paris, France
Benyahya, L:
Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Serv Neurol, Sclerose Plaques Pathol Myeline & Neuroinflammat, Lyon, France
Trouillet-Assant, S:
Montpellier Univ Hosp, Montpellier, France
Dyon-Tafani, V:
Montpellier Univ Hosp, Montpellier, France
Tilikete, CF:
Univ Autonoma Barcelona, Vall Hebron Hosp Univ, Vall Hebron Inst Recerca, Dept Radiol IDI,Sect Neuroradiol, Barcelona, Spain
Ruet, A:
CHU Bordeaux, Serv Neurol, CHU CIC P0005, Inserm, Bordeaux, France
Bourre, B:
CHU Rouen, Neurol, Rouen, France
Deschamps, R:
Fdn Adolphe Rothschild Hosp, Paris, France
Papeix, C:
Fdn Ophtalmol Adolphe Rothschild, Paris, Ile De France, France
Maillart, E:
Fdn Ophtalmol Adolphe Rothschild, Paris, Ile De France, France
Kerschen, P:
Ctr Hosp Luxembourg, Luxembourg Ville, Luxembourg, Luxembourg
Ayrignac, X:
Montpellier Univ Hosp, Montpellier, France
Rovira, A:
Univ Autonoma Barcelona, Vall Hebron Hosp Univ, Hosp Univ Vall Hebron,Sect Neuroradiol, Vall Hebron Inst Recerca,Dept Radiol IDI, Pg Vall dHebron 119-129, Barcelona 08035, Spain
Auger, C:
Univ Autonoma Barcelona, Vall Hebron Hosp Univ, Hosp Univ Vall Hebron,Sect Neuroradiol, Vall Hebron Inst Recerca,Dept Radiol IDI, Pg Vall dHebron 119-129, Barcelona 08035, Spain
Audoin, B:
Assistance Publ Hop Marseille, Marseille, France
Montalban, X:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
Tintore, M:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
Mariotto, S:
Hosp Clin Univ Valladolid, Serv Neurol, Valladolid, Spain
Cobo-Calvo, A:
Hosp Univ Vall Hebron, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya Cemcat, Neurol Dept, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Catalunya, Spain
|